These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 33161452)

  • 1. Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015  Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis.
    Aogi K; Takeuchi H; Saeki T; Aiba K; Tamura K; Iino K; Imamura CK; Okita K; Kagami Y; Tanaka R; Nakagawa K; Fujii H; Boku N; Wada M; Akechi T; Iihara H; Ohtani S; Okuyama A; Ozawa K; Kim YI; Sasaki H; Shima Y; Takeda M; Nagasaki E; Nishidate T; Higashi T; Hirata K
    Int J Clin Oncol; 2021 Jan; 26(1):1-17. PubMed ID: 33161452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary.
    Takeuchi H; Saeki T; Aiba K; Tamura K; Aogi K; Eguchi K; Okita K; Kagami Y; Tanaka R; Nakagawa K; Fujii H; Boku N; Wada M; Akechi T; Udagawa Y; Okawa Y; Onozawa Y; Sasaki H; Shima Y; Shimoyama N; Takeda M; Nishidate T; Yamamoto A; Ikeda T; Hirata K
    Int J Clin Oncol; 2016 Feb; 21(1):1-12. PubMed ID: 26081252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis.
    Iihara H; Abe M; Wada M; Iino K; Akechi T; Imamura CK; Okuyama A; Ozawa K; Kim YI; Sasaki H; Satomi E; Takeda M; Tanaka R; Nakajima TE; Nakamura N; Nishimura J; Noda M; Hayashi K; Higashi T; Boku N; Matsumoto K; Matsumoto Y; Okita K; Yamamoto N; Aogi K
    Int J Clin Oncol; 2024 Jul; 29(7):873-888. PubMed ID: 38753042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
    Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
    Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the validity of chemotherapy-induced nausea and vomiting assessment in outpatients using the Japanese version of the MASCC antiemesis tool.
    Matsuda Y; Okita K; Furuhata T; Kutomi G; Yamashita K; Sato Y; Takimoto R; Hirata K
    Support Care Cancer; 2015 Nov; 23(11):3331-9. PubMed ID: 26003425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in compliance with Japanese antiemetic guideline for chemotherapy-induced nausea and vomiting: a nationwide survey using a distributed research network.
    Hori K; Kobayashi N; Atsumi H; Nagayama A; Kondoh M; Noge I; Kimura M; Utsugi H; Iwasaki T; Nakamura M; Kimura T
    Support Care Cancer; 2014 Apr; 22(4):969-77. PubMed ID: 24276954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey.
    Dielenseger P; Börjeson S; Vidall C; Young A; Jahn P
    Support Care Cancer; 2019 Nov; 27(11):4099-4106. PubMed ID: 30783815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses.
    Clark-Snow R; Affronti ML; Rittenberg CN
    Support Care Cancer; 2018 Feb; 26(2):557-564. PubMed ID: 28871358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan.
    Iihara H; Shimokawa M; Hayashi T; Kawazoe H; Saeki T; Aiba K; Tamura K
    Oncologist; 2020 Feb; 25(2):e373-e380. PubMed ID: 32043774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The compliance with antiemetic guidelines of Turkish medical oncologists. A survey study of Turkish Oncology Group.
    Araz M; Karaagac M; Korkmaz L; Beypinar I; Uysal M
    Curr Probl Cancer; 2019 Aug; 43(4):344-353. PubMed ID: 30497851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors affecting the implementation of guideline-based prophylactic antiemetic therapy for chemotherapy-induced nausea and vomiting in Japan: a protocol for a hospital-based qualitative study.
    Yaguchi-Saito A; Kaji Y; Matsuoka A; Okuyama A; Fujimori M; Saito J; Odawara M; Otsuki A; Uchitomi Y; Zenda S; Shimazu T
    BMJ Open; 2022 Jun; 12(6):e055473. PubMed ID: 35667723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Adherence to Antiemetic Treatment Guidelines in Patients With Chemotherapy-Induced Nausea and Vomiting in Teaching Hospitals in Tehran.
    Nikbakht Z; Rajabi M; Shahrasbi A; Roohi E; Hashemian F
    J Cancer Educ; 2021 Oct; 36(5):1022-1029. PubMed ID: 31955393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost of antiemetic therapy for chemotherapy-induced nausea and vomiting in patients receiving platinum-containing regimens in daily practice in Japan: a retrospective study.
    Hamada S; Hinotsu S; Hori K; Furuse H; Oikawa T; Kawakami J; Ozono S; Akaza H; Kawakami K
    Support Care Cancer; 2012 Apr; 20(4):813-20. PubMed ID: 21472498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.
    Bosnjak SM; Dimitrijevic J; Djordjevic F
    Curr Opin Support Palliat Care; 2016 Jun; 10(2):180-8. PubMed ID: 27028050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: A quantitative market research-based survey.
    Aapro M; Ruffo P; Panteri R; Costa S; Piovesana V
    Cancer Rep (Hoboken); 2018 Dec; 1(4):e1127. PubMed ID: 32729252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of tumor therapy-induced nausea and vomiting].
    Pikó B; Bassam A
    Magy Onkol; 2009 Mar; 53(1):39-45. PubMed ID: 19318325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. State of the Art Antiemetic Therapy for Cancer Patients.
    Lau TK; Yip CH; Yeo W
    Curr Oncol Rep; 2016 Jan; 18(1):2. PubMed ID: 26694923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
    Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
    J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan.
    Baba Y; Baba H; Yamamoto S; Shimada H; Shibata T; Miyazaki T; Yoshikawa T; Nakajima Y; Tsuji Y; Shimokawa M; Kitagawa Y; Aiba K
    Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27001532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of breakthrough and prevention of refractory chemotherapy-induced nausea and vomiting in pediatric cancer patients: Clinical practice guideline update.
    Patel P; Robinson PD; Phillips R; Baggott C; Devine K; Gibson P; Guilcher GMT; Holdsworth MT; Neumann E; Orsey AD; Spinelli D; Thackray J; van de Wetering M; Cabral S; Sung L; Dupuis LL
    Pediatr Blood Cancer; 2023 Aug; 70(8):e30395. PubMed ID: 37178438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.